BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight 2020;5:140711. [PMID: 32554923 DOI: 10.1172/jci.insight.140711] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 50.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang CH, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo AM, Goss CW, O'Halloran JA, Presti RM, Kim AH, Gelman AE, Cruz CD, Lee AI, Mudd P, Chun HJ, Atkinson JP, Kulkarni HS. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. bioRxiv 2021:2021. [PMID: 33655244 DOI: 10.1101/2021.02.22.432177] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Pramod S, Goldfarb DS. Challenging patient phenotypes in the management of anaemia of chronic kidney disease. Int J Clin Pract 2021;:e14681. [PMID: 34331826 DOI: 10.1111/ijcp.14681] [Reference Citation Analysis]
3 Kanmogne M, Klein RS. Neuroprotective versus Neuroinflammatory Roles of Complement: From Development to Disease. Trends Neurosci 2021;44:97-109. [PMID: 33190930 DOI: 10.1016/j.tins.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Krishnan S, Nordqvist H, Ambikan AT, Gupta S, Sperk M, Svensson-Akusjärvi S, Mikaeloff F, Benfeitas R, Saccon E, Ponnan SM, Rodriguez JE, Nikouyan N, Odeh A, Ahlén G, Asghar M, Sällberg M, Vesterbacka J, Nowak P, Végvári Á, Sönnerborg A, Treutiger CJ, Neogi U. Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication. Mol Cell Proteomics 2021;20:100159. [PMID: 34619366 DOI: 10.1016/j.mcpro.2021.100159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González‐lópez MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüe S, Hunger RE, Ingram JR, Jemec GB, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, Macleod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, Nikiphorou E, Nikolakis G, Nogueira da Costa A, Okun MM, Orenstein LA, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepietowski JC, Tzellos T, Wang B, van der Zee HH. What causes hidradenitis suppurativa ?—15 years after. Exp Dermatol 2020;29:1154-70. [DOI: 10.1111/exd.14214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
6 Ma WF, Hodonsky CJ, Turner AW, Wong D, Song Y, Mosquera JV, Ligay AV, Slenders L, Gancayco C, Pan H, Barrientos NB, Mai D, Alencar GF, Owsiany K, Owens GK, Reilly MP, Li M, Pasterkamp G, Mokry M, van der Laan SW, Khomtchouk BB, Miller CL. Enhanced single-cell RNA-seq workflow reveals coronary artery disease cellular cross-talk and candidate drug targets. Atherosclerosis 2022;340:12-22. [PMID: 34871816 DOI: 10.1016/j.atherosclerosis.2021.11.025] [Reference Citation Analysis]
7 Chang JC. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy. Vasc Health Risk Manag 2021;17:273-98. [PMID: 34103921 DOI: 10.2147/VHRM.S299357] [Reference Citation Analysis]
8 Rangchaikul P, Venketaraman V. SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations. Infect Dis Rep 2021;13:993-1008. [PMID: 34940401 DOI: 10.3390/idr13040091] [Reference Citation Analysis]
9 Rodríguez de la Concepción ML, Ainsua-Enrich E, Reynaga E, Ávila-Nieto C, Santos JR, Roure S, Mateu L, Paredes R, Puig J, Jimenez JM, Izquierdo-Useros N, Clotet B, Pedro-Botet ML, Carrillo J. High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. Life Sci Alliance 2021;4:e202001009. [PMID: 34321327 DOI: 10.26508/lsa.202001009] [Reference Citation Analysis]
10 Persson C. Early humoral defence: Contributing to confining COVID-19 to conducting airways? Scand J Immunol 2021;93:e13024. [PMID: 33523532 DOI: 10.1111/sji.13024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, Pacia SV, Azhar S. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation 2020;17:231. [PMID: 32758257 DOI: 10.1186/s12974-020-01896-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 30.0] [Reference Citation Analysis]
12 Taşlı NP, Gönen ZB, Kırbaş OK, Gökdemir NS, Bozkurt BT, Bayrakcı B, Sağraç D, Taşkan E, Demir S, Ekimci Gürcan N, Bayındır Bilgiç M, Bayrak ÖF, Yetişkin H, Kaplan B, Pavel STI, Dinç G, Serhatlı M, Çakırca G, Eken A, Aslan V, Yay M, Karakukcu M, Unal E, Gül F, Basaran KE, Ozkul Y, Şahin F, Jones OY, Tekin Ş, Özdarendeli A, Cetin M. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2. Front Immunol 2022;13:824378. [DOI: 10.3389/fimmu.2022.824378] [Reference Citation Analysis]
13 Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NAH, Alexiou A, Batiha GE. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. Int Immunopharmacol 2022;104:108516. [PMID: 35032828 DOI: 10.1016/j.intimp.2021.108516] [Reference Citation Analysis]
14 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
15 Berghäll E, Hultström M, Frithiof R, Lipcsey M, Hahn-strömberg V. The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients. Biomedicines 2022;10:934. [DOI: 10.3390/biomedicines10050934] [Reference Citation Analysis]
16 Kulkarni HS, Atkinson JP. Targeting complement activation in COVID-19. Blood 2020;136:2000-1. [PMID: 33119763 DOI: 10.1182/blood.2020008925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Tuuminen R, Hecht I, Kanclerz P. Age-related macular degeneration and mortality in SARS-CoV-2-infected patients. Acta Ophthalmol 2021;99:e969-70. [PMID: 33258211 DOI: 10.1111/aos.14685] [Reference Citation Analysis]
18 Chen J, Wang W, Tang Y, Huang XR, Yu X, Lan HY. Inflammatory stress in SARS-COV-2 associated Acute Kidney Injury. Int J Biol Sci 2021;17:1497-506. [PMID: 33907513 DOI: 10.7150/ijbs.58791] [Reference Citation Analysis]
19 Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020;220:108598. [PMID: 32961333 DOI: 10.1016/j.clim.2020.108598] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 34.0] [Reference Citation Analysis]
20 Valdez-Cruz NA, García-Hernández E, Espitia C, Cobos-Marín L, Altamirano C, Bando-Campos CG, Cofas-Vargas LF, Coronado-Aceves EW, González-Hernández RA, Hernández-Peralta P, Juárez-López D, Ortega-Portilla PA, Restrepo-Pineda S, Zelada-Cordero P, Trujillo-Roldán MA. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact 2021;20:88. [PMID: 33888152 DOI: 10.1186/s12934-021-01576-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Conway R, Konig MF, Graef ER, Webb K, Yazdany J, Kim AHJ. Inflammatory arthritis in patients with COVID-19. Transl Res 2021;232:49-59. [PMID: 33626415 DOI: 10.1016/j.trsl.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ronit A, Jørgensen SE, Roed C, Eriksson R, Iepsen UW, Plovsing RR, Storgaard M, Gustafsson F, Hansen AE, Mogensen TH. Host Genetics and Antiviral Immune Responses in Adult Patients With Multisystem Inflammatory Syndrome. Front Immunol 2021;12:718744. [PMID: 34531865 DOI: 10.3389/fimmu.2021.718744] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rando HM, MacLean AL, Lee AJ, Lordan R, Ray S, Bansal V, Skelly AN, Sell E, Dziak JJ, Shinholster L, D'Agostino McGowan L, Ben Guebila M, Wellhausen N, Knyazev S, Boca SM, Capone S, Qi Y, Park Y, Mai D, Sun Y, Boerckel JD, Brueffer C, Byrd JB, Kamil JP, Wang J, Velazquez R, Szeto GL, Barton JP, Goel RR, Mangul S, Lubiana T, Gitter A, Greene CS; COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen, . Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. mSystems 2021;6:e0009521. [PMID: 34698547 DOI: 10.1128/mSystems.00095-21] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Das A, Rana S. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. Comput Biol Chem 2021;92:107482. [PMID: 33845430 DOI: 10.1016/j.compbiolchem.2021.107482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bery AI, Kulkarni HS, Kreisel D. Editorial: COVID-19 immunology and organ transplantation. Curr Opin Organ Transplant 2021;26:258-65. [PMID: 33651004 DOI: 10.1097/MOT.0000000000000862] [Reference Citation Analysis]
26 Sánchez-Ramón S, Faure F, Jolles S, Leboyer M, Tremblay MÈ. Editorial: The Crossroads Between Immunological Disorders and Neuropsychiatric Diseases. A Case for Schizophrenia. Front Cell Neurosci 2021;15:733997. [PMID: 34421545 DOI: 10.3389/fncel.2021.733997] [Reference Citation Analysis]
27 Hayley S, Sun H. Neuroimmune multi-hit perspective of coronaviral infection. J Neuroinflammation 2021;18:231. [PMID: 34645457 DOI: 10.1186/s12974-021-02282-0] [Reference Citation Analysis]
28 Dürvanger Z, Boros E, Nagy ZA, Hegedüs R, Megyeri M, Dobó J, Gál P, Schlosser G, Ángyán AF, Gáspári Z, Perczel A, Harmat V, Mező G, Menyhárd DK, Pál G. Directed Evolution-Driven Increase of Structural Plasticity Is a Prerequisite for Binding the Complement Lectin Pathway Blocking MASP-Inhibitor Peptides. ACS Chem Biol 2022. [PMID: 35378038 DOI: 10.1021/acschembio.2c00114] [Reference Citation Analysis]
29 Rabaan AA, Al-Ahmed SH, Garout MA, Al-Qaaneh AM, Sule AA, Tirupathi R, Mutair AA, Alhumaid S, Hasan A, Dhawan M, Tiwari R, Sharun K, Mohapatra RK, Mitra S, Emran TB, Bilal M, Singh R, Alyami SA, Moni MA, Dhama K. Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. Pathogens 2021;10:565. [PMID: 34066983 DOI: 10.3390/pathogens10050565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
30 Huțanu A, Georgescu AM, Andrejkovits AV, Au W, Dobreanu M. Insights into Innate Immune Response Against SARS-CoV-2 Infection. Revista Romana de Medicina de Laborator 2021;29:255-69. [DOI: 10.2478/rrlm-2021-0022] [Reference Citation Analysis]
31 Liu T, Balzano-Nogueira L, Lleo A, Conesa A. Transcriptional Differences for COVID-19 Disease Map Genes between Males and Females Indicate a Different Basal Immunophenotype Relevant to the Disease. Genes (Basel) 2020;11:E1447. [PMID: 33271804 DOI: 10.3390/genes11121447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Synowiec A, Szczepański A, Barreto-Duran E, Lie LK, Pyrc K. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. Clin Microbiol Rev 2021;34:e00133-20. [PMID: 33441314 DOI: 10.1128/CMR.00133-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
33 Malaquias MAS, Gadotti AC, Motta-Junior JDS, Martins APC, Azevedo MLV, Benevides APK, Cézar-Neto P, Panini do Carmo LA, Zeni RC, Raboni SM, Fonseca AS, Machado-Souza C, Moreno-Amaral AN, de Noronha L. The role of the lectin pathway of the complement system in SARS-CoV-2 lung injury. Transl Res 2021;231:55-63. [PMID: 33221483 DOI: 10.1016/j.trsl.2020.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Kamel MH, Yin W, Zavaro C, Francis JM, Chitalia VC. Hyperthrombotic Milieu in COVID-19 Patients. Cells 2020;9:E2392. [PMID: 33142844 DOI: 10.3390/cells9112392] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
35 Sattui SE, Crow MK, Navarro-Millán I. The role of immunomodulatory medications in the treatment of COVID-19. Curr Opin Rheumatol 2021;33:431-45. [PMID: 34397605 DOI: 10.1097/BOR.0000000000000817] [Reference Citation Analysis]
36 Villar M, Urra JM, Rodríguez-Del-Río FJ, Artigas-Jerónimo S, Jiménez-Collados N, Ferreras-Colino E, Contreras M, de Mera IGF, Estrada-Peña A, Gortázar C, de la Fuente J. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology. Front Immunol 2021;12:730710. [PMID: 34566994 DOI: 10.3389/fimmu.2021.730710] [Reference Citation Analysis]
37 Ville S, Le Bot S, Chapelet-Debout A, Blancho G, Fremeaux-Bacchi V, Deltombe C, Fakhouri F. Atypical HUS relapse triggered by COVID-19. Kidney Int 2021;99:267-8. [PMID: 33188793 DOI: 10.1016/j.kint.2020.10.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, Madan T, Kishore U. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology 2020;225:152008. [PMID: 33130519 DOI: 10.1016/j.imbio.2020.152008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
39 Bencheqroun H, Ahmed Y, Kocak M, Villa E, Barrera C, Mohiuddin M, Fortunet R, Iyoha E, Bates D, Okpalor C, Agbosasa O, Mohammed K, Pondell S, Mohamed A, Mohamed YI, Gok Yavuz B, Kaseb MO, Kasseb OO, Gocio MY, Tu PT, Li D, Lu J, Selim A, Ma Q, Kaseb AO. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens 2022;11:551. [DOI: 10.3390/pathogens11050551] [Reference Citation Analysis]
40 Parchure P, Joshi H, Dharmarajan K, Freeman R, Reich DL, Mazumdar M, Timsina P, Kia A. Development and validation of a machine learning-based prediction model for near-term in-hospital mortality among patients with COVID-19. BMJ Support Palliat Care 2020:bmjspcare-2020-002602. [PMID: 32963059 DOI: 10.1136/bmjspcare-2020-002602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Beaudoin CA, Jamasb AR, Alsulami AF, Copoiu L, van Tonder AJ, Hala S, Bannerman BP, Thomas SE, Vedithi SC, Torres PHM, Blundell TL. Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Comput Struct Biotechnol J 2021. [PMID: 34234921 DOI: 10.1016/j.csbj.2021.06.041] [Reference Citation Analysis]
42 Nicastro E, Verdoni L, Bettini LR, Zuin G, Balduzzi A, Montini G, Biondi A, D'Antiga L. COVID-19 in Immunosuppressed Children. Front Pediatr 2021;9:629240. [PMID: 33996683 DOI: 10.3389/fped.2021.629240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kerget F, Kerget B, Kahraman ÇY, Araz Ö, Akgün M, Uçar EY, Sağlam L. Evaluation of the relationship between pentraxin 3 (PTX3) rs2305619 (281A/G) and rs1840680 (1449A/G) polymorphisms and the clinical course of COVID-19. J Med Virol 2021. [PMID: 34314051 DOI: 10.1002/jmv.27238] [Reference Citation Analysis]
44 Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches. Rev Med Virol 2022;:e2334. [PMID: 35138001 DOI: 10.1002/rmv.2334] [Reference Citation Analysis]
45 Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020;136:2080-9. [PMID: 32877502 DOI: 10.1182/blood.2020008248] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 40.0] [Reference Citation Analysis]
46 Blagova O, Varionchik N, Zaidenov V, Savina P, Sarkisova N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol 2021;51:893-902. [PMID: 33368288 DOI: 10.1002/eji.202048930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 2020;130:6151-7. [PMID: 32759504 DOI: 10.1172/JCI141374] [Cited by in Crossref: 148] [Cited by in F6Publishing: 113] [Article Influence: 74.0] [Reference Citation Analysis]
48 Bibert S, Guex N, Lourenco J, Brahier T, Papadimitriou-Olivgeris M, Damonti L, Manuel O, Liechti R, Götz L, Tschopp J, Quinodoz M, Vollenweider P, Pagani JL, Oddo M, Hügli O, Lamoth F, Erard V, Voide C, Delorenzi M, Rufer N, Candotti F, Rivolta C, Boillat-Blanco N, Bochud PY; RegCOVID Study Group. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol 2021;12:666163. [PMID: 34135895 DOI: 10.3389/fimmu.2021.666163] [Reference Citation Analysis]
49 Perico L, Morigi M, Galbusera M, Pezzotta A, Gastoldi S, Imberti B, Perna A, Ruggenenti P, Donadelli R, Benigni A, Remuzzi G. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Front Immunol 2022;13:827146. [DOI: 10.3389/fimmu.2022.827146] [Reference Citation Analysis]
50 Scozzi D, Cano M, Ma L, Zhou D, Zhu JH, O'Halloran JA, Goss C, Rauseo AM, Liu Z, Peritore V, Rocco M, Ricci A, Amodeo R, Aimati L, Ibrahim M, Hachem R, Kreisel D, Mudd PA, Kulkarni HS, Gelman AE. Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19. bioRxiv 2020:2020. [PMID: 32766574 DOI: 10.1101/2020.07.30.227553] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Milani N, Najafpour M, Mohebbi M. Case series: Rare cases of thyroid storm in COVID-19 patients. Clin Case Rep 2021;9:e04772. [PMID: 34504698 DOI: 10.1002/ccr3.4772] [Reference Citation Analysis]
52 Howell MC, Green R, McGill AR, Kahlil RM, Dutta R, Mohapatra SS, Mohapatra S. Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs. Front Immunol 2021;12:700705. [PMID: 34899680 DOI: 10.3389/fimmu.2021.700705] [Reference Citation Analysis]
53 Keshavarz F, Ghalamfarsa F, Javdansirat S, Hasanzadeh S, Azizi A, Sabz G, Salehi M, Ghalamfarsa G. Patients with Covid 19 have significantly reduced CH50 activity. Virusdisease 2021;:1-9. [PMID: 34631971 DOI: 10.1007/s13337-021-00710-6] [Reference Citation Analysis]
54 Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res 2022. [PMID: 35192185 DOI: 10.1007/s12026-022-09265-0] [Reference Citation Analysis]
55 Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, Martin KA, Chun HJ, Hwa J. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol 2021;18:194-209. [PMID: 33214651 DOI: 10.1038/s41569-020-00469-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
56 Alexaki VI, Henneicke H. The Role of Glucocorticoids in the Management of COVID-19. Horm Metab Res 2021;53:9-15. [PMID: 33207372 DOI: 10.1055/a-1300-2550] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Quenzer F, Smyres C, Tabarez N, Singh S, LaFree A, Tomaszewski C, Hayden SR. Large Cerebellar Stroke in a Young COVID-19-Positive Patient: Case Report. J Emerg Med 2021;61:29-36. [PMID: 33863570 DOI: 10.1016/j.jemermed.2021.02.004] [Reference Citation Analysis]
58 Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, Fazlinejad R, Mohammadi-Samani S, Firouzabadi N, Hosseini M, Farjadian F. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol 2021;16:1415-51. [PMID: 34812049 DOI: 10.2217/fmb-2021-0116] [Reference Citation Analysis]
59 Jeong HH, Jia J, Dai Y, Simon LM, Zhao Z. Investigating Cellular Trajectories in the Severity of COVID-19 and Their Transcriptional Programs Using Machine Learning Approaches. Genes (Basel) 2021;12:635. [PMID: 33923155 DOI: 10.3390/genes12050635] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Noordergraaf GJ, Meertens MJHE. Editorial on: "Complement Activation is associated with poor outcome after out-of-hospital Cardiac Arrest". Resuscitation 2021:S0300-9572(21)00280-X. [PMID: 34363858 DOI: 10.1016/j.resuscitation.2021.07.028] [Reference Citation Analysis]
61 Loh JT, Zhang B, Teo JKH, Lai RC, Choo ABH, Lam KP, Lim SK. Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes. Cytotherapy 2022:S1465-3249(22)00018-4. [PMID: 35177337 DOI: 10.1016/j.jcyt.2021.12.003] [Reference Citation Analysis]
62 Rahman MH, Rana HK, Peng S, Kibria MG, Islam MZ, Mahmud SMH, Moni MA. Bioinformatics and system biology approaches to identify pathophysiological impact of COVID-19 to the progression and severity of neurological diseases. Comput Biol Med 2021;138:104859. [PMID: 34601390 DOI: 10.1016/j.compbiomed.2021.104859] [Reference Citation Analysis]
63 Sriram K, Insel PA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev 2021;101:545-67. [PMID: 33124941 DOI: 10.1152/physrev.00035.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
64 Kronbichler A, Geetha D, Smith RM, Egan AC, Bajema IM, Schönermarck U, Mahr A, Anders HJ, Bruchfeld A, Cid MC, Jayne DRW. The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum. Autoimmun Rev 2021;:102986. [PMID: 34718165 DOI: 10.1016/j.autrev.2021.102986] [Reference Citation Analysis]
65 Castro P, Palomo M, Moreno-Castaño AB, Fernández S, Torramadé-Moix S, Pascual G, Martinez-Sanchez J, Richardson E, Téllez A, Nicolas JM, Carreras E, Richardson PG, Badimon JJ, Escolar G, Diaz-Ricart M. Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications? Cardiovasc Drugs Ther 2021. [PMID: 34097193 DOI: 10.1007/s10557-021-07207-w] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
66 Apostolidis SA, Sarkar A, Giannini HM, Goel RR, Mathew D, Suzuki A, Baxter AE, Greenplate AR, Alanio C, Abdel-Hakeem M, Oldridge DA, Giles J, Wu JE, Chen Z, Huang YJ, Pattekar A, Manne S, Kuthuru O, Dougherty J, Weiderhold B, Weisman AR, Ittner CAG, Gouma S, Dunbar D, Frank I, Huang AC, Vella LA, Reilly JP, Hensley SE, Rauova L, Zhao L, Meyer NJ, Poncz M, Abrams CS, Wherry EJ; UPenn COVID Processing Unit. Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19. bioRxiv 2021:2021. [PMID: 33972943 DOI: 10.1101/2021.05.01.442279] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord 2020. [PMID: 33241508 DOI: 10.1007/s11154-020-09615-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
68 Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol 2021;101:108255. [PMID: 34688149 DOI: 10.1016/j.intimp.2021.108255] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
69 Ilera V, Delfino LC, Zunino A, Glikman P, Drnovsek M, Reyes A, Dios A, Toibaro J, Pachioli V, Lannes N, Guida A, Gauna A. Correlation between inflammatory parameters and pituitary-thyroid axis in patients with COVID-19. Endocrine 2021;74:455-60. [PMID: 34515958 DOI: 10.1007/s12020-021-02863-2] [Reference Citation Analysis]
70 Bunprakob S, Hemachudha P, Ruchisrisarod C, Supharatpariyakorn T, Hemachudha T. IP-10 and complement activation as friend or foe in COVID-19. Int J Immunopathol Pharmacol 2022;36:039463202210962. [DOI: 10.1177/03946320221096202] [Reference Citation Analysis]
71 Flieder T, Vollmer T, Müller B, Dreier J, Fischer B, Knabbe C, Birschmann I. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. PLoS One 2021;16:e0247665. [PMID: 33621254 DOI: 10.1371/journal.pone.0247665] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Fassan M, Collesei A, Angerilli V, Sbaraglia M, Fortarezza F, Pezzuto F, De Gaspari M, Businello G, Moni M, Rizzo S, Traverso G, Colosso V, Taschin E, Lunardi F, Valls AF, Schiavi F, Basso C, Calabrese F, Dei Tos AP. Multi-Design Differential Expression Profiling of COVID-19 Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory Pathways and SFTPC Impaired Transcription. Cells 2022;11:1011. [DOI: 10.3390/cells11061011] [Reference Citation Analysis]
73 Kim AHJ, Wu X, Atkinson JP. The beneficial and pathogenic roles of complement in COVID-19. Cleve Clin J Med 2020. [PMID: 33115882 DOI: 10.3949/ccjm.87a.ccc065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Jiménez D, Torres Arias M. Immunouniverse of SARS-CoV-2. Immunol Med 2022;:1-39. [PMID: 35502127 DOI: 10.1080/25785826.2022.2066251] [Reference Citation Analysis]
75 Vinciguerra M, Romiti S, Sangiorgi GM, Rose D, Miraldi F, Greco E. SARS-CoV-2 and Atherosclerosis: Should COVID-19 Be Recognized as a New Predisposing Cardiovascular Risk Factor? J Cardiovasc Dev Dis 2021;8:130. [PMID: 34677199 DOI: 10.3390/jcdd8100130] [Reference Citation Analysis]
76 Soltani Zangbar H, Gorji A, Ghadiri T. A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View. Mol Neurobiol 2021;58:536-49. [PMID: 32981023 DOI: 10.1007/s12035-020-02149-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
77 Rahman EZ, Shah P, Ong JE, Goldberg M, Ong SS. Purtscher-like retinopathy in a patient with COVID-19 and disseminated intravascular coagulation. Am J Ophthalmol Case Rep 2021;24:101229. [PMID: 34796309 DOI: 10.1016/j.ajoc.2021.101229] [Reference Citation Analysis]
78 Fox SE, Falgout L, Vander Heide RS. COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism. Cardiovasc Pathol 2021;54:107361. [PMID: 34174415 DOI: 10.1016/j.carpath.2021.107361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes 2020;12:895-908. [PMID: 32671936 DOI: 10.1111/1753-0407.13085] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
80 Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Frémeaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front Immunol 2021;12:680567. [PMID: 34248962 DOI: 10.3389/fimmu.2021.680567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Gauchel N, Rieder M, Krauel K, Goller I, Jeserich M, Salzer U, Venhoff AC, Baldus N, Pollmeier L, Wirth L, Kern W, Rieg S, Busch HJ, Hofmann M, Bode C, Duerschmied D, Lother A, Heger LA. Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease. J Thromb Thrombolysis 2021. [PMID: 34904186 DOI: 10.1007/s11239-021-02617-x] [Reference Citation Analysis]
82 Read SA, Gloss BS, Liddle C, George J, Ahlenstiel G. Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. J Inflamm Res 2021;14:1257-70. [PMID: 33833547 DOI: 10.2147/JIR.S301476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Sadeghmousavi S, Rezaei N. COVID-19 infection and stroke risk. Rev Neurosci 2021;32:341-9. [PMID: 33580645 DOI: 10.1515/revneuro-2020-0066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
85 Jacob CO. On the genetics and immunopathogenesis of COVID-19. Clin Immunol 2020;220:108591. [PMID: 32920210 DOI: 10.1016/j.clim.2020.108591] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
86 Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultström M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol 2021;12:627579. [PMID: 33692801 DOI: 10.3389/fimmu.2021.627579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
87 Hirschenberger M, Hunszinger V, Sparrer KMJ. Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells 2021;10:2134. [PMID: 34440903 DOI: 10.3390/cells10082134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Tsiftsoglou SA. SARS-CoV-2 associated Complement genetic variants possibly deregulate the activation of the Alternative pathway affecting the severity of infection. Mol Immunol 2021;135:421-5. [PMID: 33838929 DOI: 10.1016/j.molimm.2021.03.021] [Reference Citation Analysis]
89 Landau N, Shoenfeld Y, Negru L, Segal G. Exploring the pathways of inflammation and coagulopathy in COVID-19: A narrative tour into a viral rabbit hole. Int Rev Immunol 2021;:1-9. [PMID: 34678120 DOI: 10.1080/08830185.2021.1993211] [Reference Citation Analysis]
90 Naeini MB, Sahebi M, Nikbakht F, Jamshidi Z, Ahmadimanesh M, Hashemi M, Ramezani J, Miri HH, Yazdian-Robati R. A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19. Obes Med 2021;22:100323. [PMID: 33521379 DOI: 10.1016/j.obmed.2021.100323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
91 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]
92 Oh JW, Yoon CH, Ryu JS, Kim KP, Kim MK. Proteomics Analysis of Aqueous Humor and Rejected Graft in Pig-to-Non-Human Primate Corneal Xenotransplantation. Front Immunol 2022;13:859929. [DOI: 10.3389/fimmu.2022.859929] [Reference Citation Analysis]
93 De Sanctis JB, García AH, Moreno D, Hajduch M. Coronavirus infection: An immunologists' perspective. Scand J Immunol 2021;93:e13043. [PMID: 33783027 DOI: 10.1111/sji.13043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
94 Naguib R. Potential relationships between COVID-19 and the thyroid gland: an update. J Int Med Res 2022;50:3000605221082898. [PMID: 35226548 DOI: 10.1177/03000605221082898] [Reference Citation Analysis]
95 Sheerin D, Abhimanyu, Wang X, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. medRxiv 2020:2020. [PMID: 33269371 DOI: 10.1101/2020.11.25.20236646] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Aguiar VRC, Augusto DG, Castelli EC, Hollenbach JA, Meyer D, Nunes K, Petzl-Erler ML. An immunogenetic view of COVID-19. Genet Mol Biol 2021;44:e20210036. [PMID: 34436508 DOI: 10.1590/1678-4685-GMB-2021-0036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Napolitano F, Di Spigna G, Vargas M, Iacovazzo C, Pinchera B, Spalletti Cernia D, Ricciardone M, Covelli B, Servillo G, Gentile I, Postiglione L, Montuori N. Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. J Clin Med 2021;10:4914. [PMID: 34768433 DOI: 10.3390/jcm10214914] [Reference Citation Analysis]
99 Al-Gburi S, Beissert S, Günther C. Molecular mechanisms of vasculopathy and coagulopathy in COVID-19. Biol Chem 2021;402:1505-18. [PMID: 34657406 DOI: 10.1515/hsz-2021-0245] [Reference Citation Analysis]
100 Huber S, Massri M, Grasse M, Fleischer V, Kellnerová S, Harpf V, Knabl L, Knabl L Sr, Heiner T, Kummann M, Neurauter M, Rambach G, Speth C, Würzner R. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections. Viruses 2021;13:2376. [PMID: 34960645 DOI: 10.3390/v13122376] [Reference Citation Analysis]
101 Daneshgar N, Liang P, Michels CJ, Nester CM, Harshman LA, Dai D. Case Report: Clinical and Pathological Findings of a Recurrent C3 Glomerulopathy With Superimposed Membranoproliferative Glomerulonephritis Pattern and Cryoglobulinemia Associated With COVID-19. Front Pediatr 2022;10:827466. [DOI: 10.3389/fped.2022.827466] [Reference Citation Analysis]
102 Mir TH. Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies? Crit Rev Oncol Hematol 2021;162:103347. [PMID: 33940139 DOI: 10.1016/j.critrevonc.2021.103347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Blagova OV, Varionchik NV, Zaydenov VA, Savina PO, Sarkisova ND. Anticardiac antibodies in patients with severe and moderate COVID-19 (correlations with the clinical performance and prognosis). Russ J Cardiol 2020;25:4054. [DOI: 10.15829/29/1560-4071-2020-4054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
104 Zuo Y, Kanthi Y, Knight JS, Kim AHJ. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol 2021;35:101661. [PMID: 33526325 DOI: 10.1016/j.berh.2021.101661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
105 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
106 Poutoglidou F, Saitis A, Kouvelas D. Ibuprofen and COVID-19 disease: separating the myths from facts. Expert Rev Respir Med 2021;15:979-83. [PMID: 34196258 DOI: 10.1080/17476348.2021.1951239] [Reference Citation Analysis]
107 Al-Kindi S, Zidar DA. COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. Transl Res 2021:S1931-5244(21)00268-1. [PMID: 34780967 DOI: 10.1016/j.trsl.2021.11.005] [Reference Citation Analysis]
108 Kant S, Menez SP, Hanouneh M, Fine DM, Crews DC, Brennan DC, Sperati CJ, Jaar BG. The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. BMC Nephrol 2020;21:449. [PMID: 33109103 DOI: 10.1186/s12882-020-02112-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
109 Taoufik Y, de Goër de Herve MG, Corgnac S, Durrbach A, Mami-Chouaib F. When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Front Immunol 2021;12:692598. [PMID: 34630382 DOI: 10.3389/fimmu.2021.692598] [Reference Citation Analysis]
110 Scozzi D, Cano M, Ma L, Zhou D, Zhu JH, O'Halloran JA, Goss C, Rauseo AM, Liu Z, Sahu SK, Peritore V, Rocco M, Ricci A, Amodeo R, Aimati L, Ibrahim M, Hachem R, Kreisel D, Mudd PA, Kulkarni HS, Gelman AE. Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19. JCI Insight 2021;6:143299. [PMID: 33444289 DOI: 10.1172/jci.insight.143299] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
111 Thomas G, Hirter K, Frederick E, Hausburg M, Bar-or R, Mulugeta Y, Roshon M, Mains C, Bar-or D. AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC. transl med commun 2022;7. [DOI: 10.1186/s41231-022-00110-y] [Reference Citation Analysis]
112 Sahu SK, Kulkarni DH, Ozanturk AN, Ma L, Kulkarni HS. Emerging roles of the complement system in host-pathogen interactions. Trends Microbiol 2021:S0966-842X(21)00213-4. [PMID: 34600784 DOI: 10.1016/j.tim.2021.09.002] [Reference Citation Analysis]
113 Tangye SG, Bucciol G, Meyts I. Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity. Curr Opin Allergy Clin Immunol 2021;21:515-24. [PMID: 34494617 DOI: 10.1097/ACI.0000000000000786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Matli K, Farah R, Maalouf M, Chamoun N, Costanian C, Ghanem G. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. Open Heart 2021;8:e001628. [PMID: 34099529 DOI: 10.1136/openhrt-2021-001628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clinics in Dermatology 2021;39:934-65. [DOI: 10.1016/j.clindermatol.2021.07.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Olson N, Eckhardt D, Delano A. New-Onset Bullous Pemphigoid in a COVID-19 Patient. Case Rep Dermatol Med 2021;2021:5575111. [PMID: 34211788 DOI: 10.1155/2021/5575111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 . Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol 2021;6:eabh2259. [PMID: 34446527 DOI: 10.1126/sciimmunol.abh2259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
118 Yang Q, Wijerathne H, Langston JC, Kiani MF, Kilpatrick LE. Emerging Approaches to Understanding Microvascular Endothelial Heterogeneity: A Roadmap for Developing Anti-Inflammatory Therapeutics. Int J Mol Sci 2021;22:7770. [PMID: 34360536 DOI: 10.3390/ijms22157770] [Reference Citation Analysis]
119 Jarlhelt I, Nielsen SK, Jahn CXH, Hansen CB, Pérez-Alós L, Rosbjerg A, Bayarri-Olmos R, Skjoedt MO, Garred P. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation. Front Immunol 2021;12:767981. [PMID: 34804055 DOI: 10.3389/fimmu.2021.767981] [Reference Citation Analysis]
120 Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Front Immunol 2021;12:714511. [PMID: 34290717 DOI: 10.3389/fimmu.2021.714511] [Reference Citation Analysis]
121 Magnani HN. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection. Clin Appl Thromb Hemost 2021;27:1076029620977702. [PMID: 33539214 DOI: 10.1177/1076029620977702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
122 Deravi N, Ahsan E, Fathi M, Hosseini P, Yaghoobpoor S, Lotfi R, Pourbagheri-Sigaroodi A, Bashash D. Complement inhibition: A possible therapeutic approach in the fight against Covid-19. Rev Med Virol 2021;:e2316. [PMID: 34873779 DOI: 10.1002/rmv.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Subramaniam S, Ruf W, Bosmann M. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. Br J Pharmacol 2021. [PMID: 34235728 DOI: 10.1111/bph.15587] [Reference Citation Analysis]
124 Díaz-garcía E, García-tovar S, Alfaro E, Zamarrón E, Mangas A, Galera R, Ruíz-hernández JJ, Solé-violán J, Rodríguez-gallego C, Van-den-rym A, Pérez-de-diego R, Nanwani-nanwani K, López-collazo E, García-rio F, Cubillos-zapata C. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation. Front Immunol 2022;13:847894. [DOI: 10.3389/fimmu.2022.847894] [Reference Citation Analysis]
125 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Xu B, Lei Y, Ren X, Yin F, Wu W, Sun Y, Wang X, Sun Q, Yang X, Wang X, Zhang R, Li Z, Fang S, Liu J. SOD1 is a Possible Predictor of COVID-19 Progression as Revealed by Plasma Proteomics. ACS Omega 2021;6:16826-36. [PMID: 34250342 DOI: 10.1021/acsomega.1c01375] [Reference Citation Analysis]
127 Sunkara H, Dewan SMR. Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management. Int Immunopharmacol 2021;99:108049. [PMID: 34426104 DOI: 10.1016/j.intimp.2021.108049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Choi HM, Moon SY, Yang HI, Kim KS. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. Int J Mol Sci 2021;22:1737. [PMID: 33572274 DOI: 10.3390/ijms22041737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 Santos NB, Vaz da Silva ZE, Gomes C, Reis CA, Amorim MJ. Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology. PLoS Pathog 2021;17:e1009381. [PMID: 34197564 DOI: 10.1371/journal.ppat.1009381] [Reference Citation Analysis]